Shattuck Labs, Inc.
Informe acción NasdaqGS:STTK
Capitalización de mercado: US$56.3m
Shattuck Labs Crecimiento futuro
Future controles de criterios 0/6 Se prevé que los ingresos y los beneficios de Shattuck Labs disminuyan a un ritmo anual de 42.3% y 15.5% respectivamente. Se espera que el BPA crezca en un 2.1% al año. Se prevé que la rentabilidad financiera sea de -132.3% en 3 años.
Información clave
-15.5%
Tasa de crecimiento de los beneficios
2.1%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs 27.3% Tasa de crecimiento de los ingresos -42.3% Rentabilidad financiera futura -132.3% Cobertura de analistas Low
Última actualización 02 Oct 2024
Actualizaciones recientes sobre el crecimiento futuro
Consensus revenue estimates decrease by 19%, EPS upgraded Oct 02
Price target decreased by 27% to US$8.00 Oct 01
Consensus revenue estimates increase by 23% Aug 16
Price target decreased by 7.9% to US$14.50 Jun 15
Consensus revenue estimates increase by 15% May 24
Consensus revenue estimates increase by 159% May 09
Mostrar todas las actualizaciones
New minor risk - Market cap size Oct 02
Consensus revenue estimates decrease by 19%, EPS upgraded Oct 02
Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely? Oct 02
Price target decreased by 27% to US$8.00 Oct 01
Shattuck Labs, Inc. Announces Strategic Pipeline Prioritization to Include the Discontinuation of Its Clinical Program, SL-172154 Oct 01
Consensus revenue estimates increase by 23% Aug 16
New major risk - Revenue and earnings growth Aug 04
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 02
Co-Founder recently bought US$50k worth of stock Jun 27
Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation Jun 15
Price target decreased by 7.9% to US$14.50 Jun 15
Shattuck Labs, Inc. Announces Committee Appointments Jun 13
Consensus revenue estimates increase by 15% May 24
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine (Aza) in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant (Tp53m) Acute Myeloid Leukemia (Aml) Patients At the European Hematology Association (Eha) 2024 Congress May 16
Consensus revenue estimates increase by 159% May 09
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 03
Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024 Apr 24
Consensus revenue estimates increase by 170% Apr 05
General Counsel notifies of intention to sell stock Mar 10
Insufficient new directors Mar 08
Shattuck Labs, Inc. Announces Board Appointments Mar 05
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 03
Chief Financial Officer recently sold US$250k worth of stock Jan 18
Chief Financial Officer notifies of intention to sell stock Jan 12 Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.
New minor risk - Shareholder dilution Dec 22 Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.
Price target increased by 21% to US$15.50 Dec 20
New major risk - Financial position Dec 17
Consensus revenue estimates increase by 78%, EPS downgraded Nov 16
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 07
Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting Nov 03
Consensus revenue estimates increase by 16% Sep 17
Price target decreased by 21% to US$12.80 Sep 15
Consensus revenue estimates decrease by 11% Aug 27
Consensus revenue estimates increase by 91% Aug 17
New minor risk - Market cap size Aug 02
Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth? Jun 28
New minor risk - Share price stability Jun 27
Consensus EPS estimates upgraded to US$2.03 loss May 16
We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate Mar 09
Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 17
Consensus forecasts updated Nov 25
Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth? Nov 23
Consensus revenue estimates increase by 264% Nov 16
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021) Nov 11
Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021) Aug 12
Shattuck Labs GAAP EPS of -$0.65 misses by $0.06 Aug 11
We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate Jul 26 Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint May 13
Price target decreased to US$25.50 Apr 27
High number of new directors Apr 27
Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022 Apr 22
Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting Apr 09
Consensus forecasts updated Apr 02
Consensus forecasts updated Mar 22
Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates Mar 18
Price target decreased to US$39.00 Mar 16
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 16
Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans? Feb 25
Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc Feb 01
Lead Independent Director recently bought US$56k worth of stock Jan 21
Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely? Nov 23
Chief Financial Officer exercised options to buy US$250k worth of stock. Nov 14
Third quarter 2021 earnings released: US$0.41 loss per share (vs US$1.54 loss in 3Q 2020) Nov 11
High number of new and inexperienced directors Nov 02
General Counsel notifies of intention to sell stock Oct 24
We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth Aug 24
Consensus revenue estimates fall to US$2.31m Aug 19
General Counsel notifies of intention to sell stock Jul 18
General Counsel notifies of intention to sell stock Jun 18
Shattuck Labs names Abhinav Shukla as chief technical officer Jun 01
Co-Founder & Chairman of the Board notifies of intention to sell stock May 25
Co-Founder & Chairman of the Board notifies of intention to sell stock May 13
First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.86 loss in 1Q 2020) May 11
Shattuck Labs EPS beats by $0.11, beats on revenue May 10
Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation May 07
Chief Financial Officer notifies of intention to sell stock May 03
Chief Financial Officer notifies of intention to sell stock Apr 18
Shattuck Labs, Inc. Promotes Andrew R. Neill to Chief Financial Officer Mar 17
Full year 2020 earnings released: US$2.36 loss per share (vs US$3.17 loss in FY 2019) Mar 17
Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful? Mar 08
We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely Jan 12
Previsiones de crecimiento de beneficios e ingresos NasdaqGS:STTK - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions) Fecha Ingresos Beneficios Flujo de caja libre Flujo de caja operativo Núm. de analistas medio 12/31/2026 N/A -94 -124 N/A 3 12/31/2025 N/A -60 -96 N/A 3 12/31/2024 3 -78 -94 N/A 4 6/30/2024 4 -85 -63 -63 N/A 3/31/2024 3 -85 -71 -71 N/A 12/31/2023 2 -87 -82 -81 N/A 9/30/2023 1 -95 -87 -86 N/A 6/30/2023 1 -92 -99 -97 N/A 3/31/2023 1 -98 -104 -95 N/A 12/31/2022 1 -102 -106 -94 N/A 9/30/2022 30 -69 -102 -89 N/A 6/30/2022 32 -61 -87 -74 N/A 3/31/2022 28 -58 -80 -72 N/A 12/31/2021 30 -45 -65 -57 N/A 9/30/2021 1 -65 -59 -52 N/A 6/30/2021 2 -59 -56 -51 N/A 3/31/2021 9 -42 -38 -34 N/A 12/31/2020 10 -37 -34 -34 N/A 9/30/2020 11 -32 -28 -27 N/A 6/30/2020 11 -27 -24 -23 N/A 3/31/2020 10 -26 -29 -28 N/A 12/31/2019 10 -24 -21 -21 N/A 12/31/2018 22 -7 -8 -7 N/A
Mostrar más
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que STTK siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que STTK siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que STTK siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos de STTK disminuyan en los próximos 3 años (-42.3% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos de STTK disminuyan en los próximos 3 años (-42.3% al año).
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: STTK se prevé que no sea rentable en 3 años.
Descubre empresas en crecimiento Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
